Mesoblast Limited, a biopharmaceutical company, develops and markets allogeneic cellular drugs. The company is headquartered in Melbourne, Australia. Show more

55 COLLINS STREET, MELBOURNE, VIC, AUSTRALIA, 3000, Melbourne, VIC, 3000, USA

https://www.mesoblast.com

BIOTECHNOLOGY

HEALTHCARE

Start AI Chat

Market Cap

2.205B

52 Wk Range

$12.66 - $21.50

Previous Close

$17.00

Open

$16.80

Volume

177,705

Day Range

$16.44 - $16.80

Enterprise Value

2.184B

Cash

129.6M

Avg Qtr Burn

-4.111M

Insider Ownership

5.04%

Institutional Own.

3.28%

Qtr Updated

12/31/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
RYONCIL™ (Remestemcel-L) Details Acute graft-versus host disease	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Rexlemestrocel-L (Rexlemestrocel-L) (Mesenchymal Precursor Cells) Details Prevention Of Life-Threatening Gastrointestinal Bleeding In End-Stage Heart Failure Patients With A Left Ventricular Assist Device (LVAD)	BLA Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
REVASCOR® (Rexlemestrocel) Details Pediatric Hypoplastic Left Heart Syndrome (HLHS)	BLA Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
REVASCOR® (Rexlemestrocel) Details Ischemic CHF with reduced ejection fraction (HFrEF) and inflammation	BLA Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Rexlemestrocel Details Chronic lower back pain (CLBP)	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Ryoncil/Remestemcel-L-Rknd (Remestemcel-L-Rknd) (Mesenchymal Stromal Cells) Details Steroid-Refractory Acute Graft-Versus-Host Disease In Adults	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Ryoncil/Remestemcel-L-Rknd (Remestemcel-L-Rknd) (Mesenchymal Stromal Cells) Details Duchenne Muscular Dystrophy	IND Acceptance decision	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Remestemcel-L (mesenchymal stem cells) Details COVID-19	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.